[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 54 of about 54
16. Bettaieb I, Mekni A, Bellil K, Haouet S, Bellil S, Kchir N, Chelly H, Zitouna M: Endometrial adenofibroma: a rare entity. Arch Gynecol Obstet; 2007 Mar;275(3):191-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial adenofibroma: a rare entity.
  • Endometrial adenofibroma is an uncommon mullerian mixed tumor composed of benign epithelial and mesenchymal components.
  • This tumor must be distinguished from other malignant lesions of the uterus, particularly adenosarcoma.
  • The authors report three cases of endometrial adenofibroma and discuss their clinical and histopathologic features.
  • [MeSH-major] Adenofibroma / pathology. Endometrial Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16858575.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Cheuk W, Chan JK: Advances in salivary gland pathology. Histopathology; 2007 Jul;51(1):1-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Newly recognized entities include: sclerosing polycystic adenosis (with recent molecular evidence supporting its neoplastic nature), sclerosing mucoepidermoid carcinoma with eosinophilia, keratocystoma, adenoma with additional stromal component (lymphadenoma, lipoadenoma and adenofibroma), cribriform adenocarcinoma of the tongue and signet ring adenocarcinoma of minor salivary gland.
  • Known tumour entities with new findings include: salivary duct carcinoma (with newly recognized mucinous, micropapillary and sarcomatoid variants), intraductal carcinoma (with controversies in terminology), mucoepidermoid carcinoma (with newly proposed grading parameters and oncocytic variant), epithelial-myoepithelial carcinoma (with newly recognized morphological variants), small cell carcinoma (with most cases being related to Merkel cell carcinoma), extranodal marginal zone B-cell lymphoma (with specific chromosomal translocation) and chronic sclerosing sialadenitis (being a component of IgG4-related sclerosing disease).
  • Progression of salivary gland tumours can take the form of malignant transformation of a benign tumour, progression from low-grade to high-grade carcinoma, dedifferentiation, or stromal invasion of an in situ carcinoma.
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Disease Progression. Gene Expression Regulation, Neoplastic. Humans

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17539914.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 142
  •  go-up   go-down


18. Tokunaga H, Akahira J, Suzuki T, Moriya T, Sasano H, Ito K, Yaegashi N: Ovarian epithelial carcinoma with estrogen-producing stroma. Pathol Int; 2007 May;57(5):285-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Her serum estradiol (E2) concentration was 83 pg/mL before treatment, and the endometrial thickness measured by transvaginal ultrasonography was 5 cm, much thicker than that expected for a woman in her 80s.
  • Immunohistochemical studies demonstrated that the enzymes required to produce estrogen were present in the tumor.
  • This case indicates that in addition to stromal tumors, such as granulosa cell tumors, theca cell tumors, adenofibroma and so on, malignant epithelial tumors with a functioning stroma should also be considered when evaluating ovarian tumors with estrogen production in the elderly.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17493177.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Estrogens; 4TI98Z838E / Estradiol
  •  go-up   go-down


19. Gallardo A, Prat J: Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol; 2009 Feb;33(2):278-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.
  • Mullerian adenosarcomas are rare mixed tumors of low malignant potential that occur mainly in the uterus and also in extrauterine locations.
  • Microscopically, they may be difficult to distinguish from adenofibromas.
  • The tumor of the fallopian tube was stage IC, and the tumors of the vagina and recto-uterine pouch were confined to their site of origin.
  • Six developed metastases and 5 of them died of tumor.
  • Both were initially underdiagnosed as adenofibromas.
  • The finding of such cases, which raises the controversy of whether or not adenofibroma exists as a tumor entity, prompted us to make a comparative immunohistochemical analysis of 23 typical adenosarcomas, 8 adenosarcomas with sarcomatous overgrowth, and 29 benign and malignant related lesions, including 7 clinically benign adenofibromas.
  • Adenosarcomas with sarcomatous overgrowth showed strong immunoreaction for Ki-67 and p53 and loss of CD10 and progesterone receptors immunostaining; in contrast, the immunoreaction for these tumor markers in typical adenosarcomas without sarcomatous overgrowth was similar to that of adenofibromas associated with favorable outcome and other benign lesions such as endometrial polyps and endometriosis.
  • These findings suggest that some of the tumors currently classified as adenofibromas, on the basis of their low mitotic count and lack of significant nuclear atypia, are, in fact, well-differentiated adenosarcomas.
  • [MeSH-major] Adenofibroma / pathology. Adenosarcoma / pathology. Genital Neoplasms, Female / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Mitotic Index. Neoplasm Staging. Tissue Array Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941402.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


20. Scurry J, van der Putte SC, Pyman J, Chetty N, Szabo R: Mammary-like gland adenoma of the vulva: review of 46 cases. Pathology; 2009;41(4):372-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unusual vulvar tumours, which have been previously reported as erosive adenomatosis, sclerosing adenosis, papillary adenofibroma, syringocystadenoma papilliferans, etc., are variants of MLG adenomas.

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404851.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 46
  •  go-up   go-down


21. Veras E, Mao TL, Ayhan A, Ueda S, Lai H, Hayran M, Shih IeM, Kurman RJ: Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol; 2009 Jun;33(6):844-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are frequently associated with endometriosis and, less often with clear cell adenofibromas.
  • We hypothesized that CCCs are a heterogeneous group of tumors, some arising from a cyst and others from an adenofibroma.
  • Various features were analyzed including: age, race, laterality, tumor size, architectural pattern (papillary, tubulo-cystic, solid, mixed patterns), grade, mitotic index, association with endometriosis including atypical endometriosis/intraepithelial carcinoma, stage and survival.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenofibroma / pathology. Cysts / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19342944.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Sokalska A, Timmerman D, Testa AC, Van Holsbeke C, Lissoni AA, Leone FP, Jurkovic D, Valentin L: Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses. Ultrasound Obstet Gynecol; 2009 Oct;34(4):462-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Within the framework of a European multicenter study, the International Ovarian Tumor Analysis study, comprising nine ultrasound centers, women with at least one adnexal mass were examined with gray-scale and color Doppler ultrasonography by experienced ultrasound examiners.
  • Using pattern recognition the examiners classified each mass as benign or malignant and suggested a specific diagnosis (e.g. dermoid cyst or endometrioma).
  • RESULTS: A total of 1066 women were included, of whom 800 had a benign mass and 266 a malignant mass.
  • The sensitivity was highest for benign teratoma/dermoid cysts (86%, 100/116), hydrosalpinges (86%, 18/21), peritoneal pseudocysts (80%, 4/5) and endometriomas (77%, 153/199), and lowest for functional cysts (17%, 4/24), paraovarian/parasalpingeal cysts (14%, 3/21), benign rare tumors (11%, 1/9), adenofibromas (8%, 3/39), simple cysts (6%, 1/18) and struma ovarii (0%, 0/5).
  • Dermoid cysts, hydrosalpinges, functional cysts, paraovarian cysts, peritoneal pseudocysts, fibromas/fibrothecomas and simple cysts were never misdiagnosed as malignancies by the ultrasound examiner, whereas more than 10% of inflammatory processes, adenofibromas and rare benign tumors including struma ovarii were misdiagnosed as malignancies.
  • CONCLUSIONS: Using subjective evaluation of gray-scale and Doppler ultrasound findings it is possible to make an almost conclusive diagnosis of a dermoid cyst, endometrioma and hydrosalpinx.
  • [MeSH-major] Adnexal Diseases / ultrasonography. Clinical Competence / standards. Pattern Recognition, Automated
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Ovarian Neoplasms / classification. Ovarian Neoplasms / ultrasonography. Predictive Value of Tests. Prognosis. Risk Factors. Sensitivity and Specificity. Ultrasonography, Doppler

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19685552.001).
  • [ISSN] 1469-0705
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


23. Boruban MC, Jaishuen A, Sirisabya N, Li Y, Zheng HG, Deavers MT, Kavanagh JJ: Ovarian endometriosis associated with carcinoma and sarcoma: case report. Eur J Gynaecol Oncol; 2008;29(4):393-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endometriosis is a common clinical disorder that shares certain characteristics, metastasis and recurrence, with malignant neoplasms.
  • Here, we report the case of a 32-year-old woman who presented with infertility and a pelvic mass.
  • The pathologic findings revealed bilateral endometrioid adenofibroma of low malignant potential, which was associated with endometrioid intraepithelial carcinoma in the left ovary and high-grade sarcoma in the right ovary.
  • The optimal treatment for endometriosis-associated ovarian cancer depends on the type of malignancy; simultaneously occurring multiple tumor types should be treated individually.
  • [MeSH-major] Carcinoma / etiology. Endometriosis / complications. Ovarian Diseases / complications. Ovarian Neoplasms / etiology. Sarcoma / etiology


2
Advertisement
4. McCluggage WG, Young RH: Ovarian sertoli-leydig cell tumors with pseudoendometrioid tubules (pseudoendometrioid sertoli-leydig cell tumors). Am J Surg Pathol; 2007 Apr;31(4):592-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The converse situation, mimicry of an endometrioid neoplasm by a sex cord-stromal tumor, has not been emphasized.
  • The proportion of the tumor made up of pseudoendometrioid tubules ranged from 10% to >90%.
  • When widespread, their presence sometimes resulted in consideration of a borderline endometrioid adenofibroma or a well-differentiated endometrioid adenocarcinoma.
  • The presence of more typical Sertoli cell elements and Leydig cells, an absence of squamous elements, endometriosis or associated adenofibroma, and the characteristic immunophenotype assist in diagnosis.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Carcinoma, Endometrioid / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Sertoli-leydig cell tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17414107.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Vang R, Shih IeM, Kurman RJ: Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol; 2009 Sep;16(5):267-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They evolve from adenofibromas or borderline tumors, have frequent mutations of the KRAS, BRAF, or ERBB2 genes, and lack TP53 mutations (Type I pathway).
  • Identification of a precursor lesion in the ovary has been elusive and therefore the origin of ovarian carcinoma has been described as de novo.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1994-2000 [15753399.001]
  • [Cites] Mod Pathol. 2005 Feb;18 Suppl 2:S19-32 [15761464.001]
  • [Cites] Am J Surg Pathol. 2005 Jun;29(6):707-23 [15897738.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1034-41 [16006797.001]
  • [Cites] Int J Gynecol Pathol. 2005 Oct;24(4):363-8 [16175083.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14004-9 [16172393.001]
  • [Cites] Am J Surg Pathol. 2005 Nov;29(11):1482-9 [16224215.001]
  • [Cites] Hum Pathol. 2005 Oct;36(10):1049-54 [16226103.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]
  • [Cites] Cancer. 2005 Dec 15;104(12):2807-16 [16284991.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):230-6 [16434898.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:123-8 [16515579.001]
  • [Cites] Int J Gynecol Cancer. 2006 Mar-Apr;16(2):484-9 [16681715.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1091-100 [16648864.001]
  • [Cites] Obstet Gynecol. 2006 Aug;108(2):361-8 [16880307.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):779-85 [16721043.001]
  • [Cites] Am J Surg Pathol. 2006 Oct;30(10):1209-21 [17001150.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5944-50 [17062665.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):703-8 [16828848.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):883-7 [16806438.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):103-13 [17145637.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18739-44 [17130457.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] Am J Surg Pathol. 2007 May;31(5):653-63 [17460447.001]
  • [Cites] Histopathology. 2007 May;50(6):773-9 [17493241.001]
  • [Cites] Int J Gynecol Cancer. 2007 May-Jun;17(3):601-6 [17504374.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):625-9 [17320156.001]
  • [Cites] Am J Surg Pathol. 2007 Jul;31(7):1007-12 [17592266.001]
  • [Cites] Am J Surg Pathol. 2007 Aug;31(8):1168-74 [17667538.001]
  • [Cites] Gynecol Oncol. 2007 Dec;107(3):398-403 [17997146.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):510-4 [18155273.001]
  • [Cites] Int J Gynecol Cancer. 2008 May-Jun;18(3):487-91 [17692090.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1239-51 [18602670.001]
  • [Cites] Histopathology. 2008 Aug;53(2):127-38 [18298580.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4160-5 [18757330.001]
  • [Cites] Am J Surg Pathol. 2008 Oct;32(10):1566-71 [18724243.001]
  • [Cites] Curr Oncol Rep. 2008 Nov;10(6):519-23 [18928667.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1667-74 [18769340.001]
  • [Cites] Am J Surg Pathol. 2008 Dec;32(12):1800-6 [18779727.001]
  • [Cites] Br J Cancer. 2008 Dec 16;99(12):2020-8 [19018267.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] Cancer Res. 2009 May 1;69(9):4036-42 [19383911.001]
  • [Cites] Am J Surg Pathol. 2009 Aug;33(8):1220-4 [19461510.001]
  • [Cites] Am J Surg Pathol. 2009 Jul;33(7):1037-41 [19238079.001]
  • [Cites] Am J Surg Pathol. 2009 Oct;33(10):1504-14 [19623034.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] J Surg Oncol. 2000 Mar;73(3):148-52 [10738268.001]
  • [Cites] J Natl Cancer Inst. 2000 Jul 5;92(13):1088-91 [10880552.001]
  • [Cites] Cancer. 2000 Nov 15;89(10):2076-84 [11066048.001]
  • [Cites] Am J Hum Genet. 2001 Mar;68(3):700-10 [11179017.001]
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):201-6 [11161860.001]
  • [Cites] Int J Gynecol Pathol. 2001 Oct;20(4):323-8 [11603214.001]
  • [Cites] J Natl Cancer Inst. 2002 Jan 2;94(1):61-7 [11773283.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):47-59 [11823973.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1396-406 [12237285.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):37-41 [12496696.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] Gynecol Oncol. 2003 Apr;89(1):148-54 [12694669.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):725-36 [12766576.001]
  • [Cites] Gynecol Oncol. 2003 Jun;89(3):447-52 [12798710.001]
  • [Cites] J Pathol. 2004 Mar;202(3):336-40 [14991899.001]
  • [Cites] Int J Gynecol Pathol. 2004 Apr;23(2):162-9 [15084845.001]
  • [Cites] Am J Surg Pathol. 2004 Apr;28(4):496-504 [15087669.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] Am J Obstet Gynecol. 2004 Apr;190(4):1039-45 [15118638.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):265-72 [15213603.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):918-33 [15297960.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):934-48 [15297961.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6915-8 [15466181.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6432-6 [15475429.001]
  • [Cites] Eur J Surg Oncol. 2004 Nov;30(9):976-81 [15498644.001]
  • [Cites] Surg Clin North Am. 1978 Feb;58(1):121-9 [644422.001]
  • [Cites] Gynecol Oncol. 1993 Sep;50(3):347-51 [8406199.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):393-6 [8774644.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1319-30 [8898836.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):663-7 [9237175.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):893-901 [9486579.001]
  • [Cites] Virchows Arch. 1999 Feb;434(2):117-20 [10071245.001]
  • [Cites] Am J Obstet Gynecol. 1950 Jan;59(1):58-67, illust [15399626.001]
  • (PMID = 19700937.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA129080-02; United States / NCI NIH HHS / CA / R01 CA129080-02; United States / NCI NIH HHS / CA / R01CA116184; United States / NCI NIH HHS / CA / R01 CA116184; United States / NCI NIH HHS / CA / R01 CA129080; United States / NCI NIH HHS / CA / R01CA129080; United States / NCI NIH HHS / CA / R01 CA103937; United States / NCI NIH HHS / CA / R01CA103937
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / ERBB2IP protein, human; 0 / KRAS protein, human; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Protein p53; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 87
  • [Other-IDs] NLM/ NIHMS139803; NLM/ PMC2745605
  •  go-up   go-down


26. Soslow RA, Ali A, Oliva E: Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases. Am J Surg Pathol; 2008 Jul;32(7):1013-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mullerian adenosarcomas (MAs) are rare mixed mesenchymal and epithelial neoplasms that occur most commonly in the uterus.
  • Although the epithelial component is typically benign, the mesenchymal component of most adenosarcomas morphologically resembles that observed in endometrial stromal tumors and is responsible for their clinical behavior.
  • Thus, the differential diagnosis usually includes not only low-grade endometrial stromal tumors, but also adenofibroma, carcinosarcoma, and embryonal rhabdomyosarcoma especially in small samples.
  • Expression of c-kit and inhibin in greater than 5% of the tumor cells was not encountered.
  • [MeSH-major] Adenosarcoma / pathology. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenofibroma / diagnosis. Biomarkers, Tumor / analysis. Cell Proliferation. Diagnosis, Differential. Female. Humans. Immunohistochemistry / methods. Rhabdomyosarcoma, Embryonal / diagnosis. Sarcoma, Endometrial Stromal / diagnosis. Stromal Cells / metabolism. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469708.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


27. Piotrowski Z, Canter DJ, Kutikov A, Al-Saleem T, Pei J, Testa JR, Uzzo RG: Metanephric adenofibroma: robotic partial nephrectomy of a large Wilms' tumor variant. Can J Urol; 2010 Aug;17(4):5309-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metanephric adenofibroma: robotic partial nephrectomy of a large Wilms' tumor variant.
  • PURPOSE: A case of the rare, benign, Wilms' tumor (WT) variant, metanephric adenofibroma (MAF), is presented.
  • Pathologic diagnosis at our institution was confirmed as a MAF by the National Wilms' Tumor Study Group (NWTSG).
  • [MeSH-major] Adenofibroma / surgery. Kidney Neoplasms / surgery. Nephrectomy / methods. Robotics. Wilms Tumor / surgery

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20735912.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


28. Chong Y, Eom M, Park KH, Chung HC, Ro JY: Adenofibroma of Skene's Duct: A Case Report. Patholog Res Int; 2010;2010:318973
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenofibroma of Skene's Duct: A Case Report.
  • Recently, the authors experienced the first case of adenofibroma arising in Skene's glands of a 62-year-old woman with coital pain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21152177.001).
  • [ISSN] 2042-003X
  • [Journal-full-title] Pathology research international
  • [ISO-abbreviation] Patholog Res Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2997287
  •  go-up   go-down


29. Ben Hassouna J, Damak T, Ben Slama A, Chargui R, Ben Dhiab T, Khomsi F, Gamoud A, Boussen H, Rahal K: Breast carcinoma arising within fibroadenomas. Report of four observations. Tunis Med; 2007 Oct;85(10):891-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Fibroadenoma is a frequent benign breast tumor affecting young woman.
  • The incidence of a carcinoma within adenofibromas is estimated at 0.1 to 0.3%.
  • AIM: The purpose of this study was to evaluate the outcome of patients with breast carcinoma arising within adenofibroma and to determine the clinical characteristics and the prognosis of this rare entity.
  • The treatment consisted of a conservative treatment in two cases and a mastectomy plus axillary node dissection in the two others.
  • CONCLUSION: Every benign mammary nodule must necessarily be verified surgically to avoid misdiagnosing any carcinomatous area because at this stage its prognosis is better.
  • [MeSH-major] Adenofibroma / pathology. Breast Neoplasms / pathology. Carcinoma / pathology. Cell Transformation, Neoplastic / pathology
  • [MeSH-minor] Adult. Breast Cyst / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy. Metaplasia. Middle Aged. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236815.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


30. Yamamoto S, Tsuda H, Takano M, Kita T, Kudoh K, Furuya K, Tamai S, Matsubara O: Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors. Mod Pathol; 2008 Feb;21(2):115-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical expression of platelet-derived growth factor receptor-alpha and receptor-beta, platelet-derived growth factor A-chain and B-chain was examined in 31 cases of clear-cell adenocarcinoma and 56 coexisting putative precursor lesions: 17 non-atypical and 19 atypical endometrioses, and 10 non-atypical and 10 atypical clear-cell adenofibroma components.
  • The frequencies of positivity for platelet-derived growth factor receptor-alpha and receptor-beta, and platelet-derived growth factor A-chain increased in accordance with higher cytologic atypia in the putative precursors: 71, 47, and 59% in the 17 non-atypical endometrioses, 84, 73, and 84% in the 19 atypical endometrioses, 0% each in the 10 non-atypical clear-cell adenofibromas, 100, 90, and 90% in the 10 atypical clear-cell adenofibromas, and 97, 97, and 100% in the 31 clear-cell adenocarcinomas, respectively.
  • Positivity for platelet-derived growth factor B-chain increased in accordance with increased atypia in clear-cell adenofibroma: 0% in non-atypical clear-cell adenofibromas, 30% in atypical clear-cell adenofibromas, and 60% in coexisting carcinomas.
  • These results indicate activation of the platelet-derived growth factor pathway in ovarian clear-cell adenocarcinomas and suggest biological differences between carcinomas that arise in association with clear-cell adenofibroma vs endometriosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Adenofibroma / metabolism. Endometriosis / metabolism. Ovarian Neoplasms / metabolism. Platelet-Derived Growth Factor / metabolism. Receptors, Platelet-Derived Growth Factor / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Female. Humans. Immunoenzyme Techniques. Neoplasms, Multiple Primary. Precancerous Conditions / metabolism. Precancerous Conditions / pathology

  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18084257.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


31. Chung YW, Bae HS, Han SI, Song JY, Kim IS, Kang JS: Endometrial mullerian adenosarcoma after toremifene treatment in breast cancer patients: a case report. J Gynecol Oncol; 2010 Dec 30;21(4):269-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After 1 year of toremifene use, the patient had a benign Mullerian adenofibroma.
  • Although toremifene is a promising anti-estrogenic agent in the treatment of breast cancer patients, clinicians should not neglect the possibility of a uterine malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Hosp Clin Fac Med Sao Paulo. 2000 Jan-Feb;55(1):17-20 [10881074.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3487-94 [11032589.001]
  • [Cites] Arch Gynecol Obstet. 2000 Sep;264(2):105-7 [11045336.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):897-902 [11286468.001]
  • [Cites] AJR Am J Roentgenol. 2003 Dec;181(6):1673-5 [14627594.001]
  • [Cites] Breast. 2006 Apr;15(2):142-57 [16289904.001]
  • [Cites] Int J Gynecol Cancer. 2006 Mar-Apr;16(2):861-5 [16681774.001]
  • [Cites] Eur J Cancer. 2009 Mar;45(4):561-71 [19062268.001]
  • [Cites] Breast Cancer Res Treat. 1993;25(1):57-63 [8518408.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1749-59 [15550579.001]
  • (PMID = 21278890.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3026307
  • [Keywords] NOTNLM ; Breast cancer / Mullerian adenofibroma / Mullerian adenosarcoma / Tamoxifen / Toremifene
  •  go-up   go-down


32. Yang JX, Han YJ, Zheng H, Luo RC: [Expression of PAK4 in breast cancer and benign breast pathological changes]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 May;30(5):981-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of PAK4 in breast cancer and benign breast pathological changes].
  • METHOD: PAK4 expression was detected in 35 cases of normal breast, 22 breast cystic hyperplasia, 28 breast adenofibroma, 37 breast cancer (including 7 non-invasive cancer, 9 early invasive cancer and 21 invasive cancer) and 13 metastatic breast cancer tissues using immunohistochemistry for a comparison of PAK4 expression and distribution.
  • PAK4 positivity rates increased in the order of normal breast tissues, benign changes (including breast cystic hyperplasea and breast adenoma), breast cancer and metastatic cancer tissues; in the cancer tissues, the positivity rates increased in the order of non-invasive breast tumor, early invasive tumor and invasive tumor tissues.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism. p21-Activated Kinases / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501374.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.11 / PAK4 protein, human; EC 2.7.11.1 / p21-Activated Kinases
  •  go-up   go-down


33. Prat J: Ovarian carcinomas, including secondary tumors: diagnostically challenging areas. Mod Pathol; 2005 Feb;18 Suppl 2:S99-111
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mucinous carcinomas of the ovary are rare and can be easily confused with metastatic mucinous carcinomas that may present clinically as a primary ovarian tumor.
  • International Federation of Gynecology and Obstetrics (FIGO) stage is the single most important prognostic factor, and stage I carcinomas have an excellent prognosis; FIGO stage is largely related to the histologic features of the ovarian tumors.
  • However, typical endometrioid glands, squamous differentiation, or an adenofibroma component are each present in 75% of these tumors whereas immunostains for calretinin and alpha-inhibin are negative.
  • Most of these tumors have a favorable outcome and they most likely represent independent primary carcinomas arising as a result of a Mullerian field effect.
  • Transitional cell carcinomas are distinguished from undifferentiated carcinomas by the presence of thick, undulating papillae with smooth luminal borders, microspaces, and tumor cells with distinctive 'urothelial' appearance.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492758.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Trans-Activators; 0 / beta Catenin; 68238-35-7 / Keratins; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 63
  •  go-up   go-down


34. McCluggage WG: Mullerian adenosarcoma of the female genital tract. Adv Anat Pathol; 2010 Mar;17(2):122-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mullerian adenosarcoma is an uncommon, but not rare, mixed tumor containing a neoplastic but benign or mildly atypical epithelial element and a sarcomatous, usually low-grade, stromal component.
  • Characteristic histologic features include a low power "phyllodes-like" architecture with leaf-like projections lined by a variety of benign Mullerian type epithelia, sometimes with squamous metaplasia.
  • The stroma may be uniformly cellular but there is typically increased cellularity around the epithelial elements, resulting in the formation of a cambium layer.
  • Using the World Health Organization definition, stromal mitotic activity of 2 or more per 10 high-power fields is required for a diagnosis of adenosarcoma but in practice the diagnosis is made with stromal mitotic activity less than this if the characteristic architecture and cambium layer is present.
  • Adenosarcoma may be confused with a variety of lesions and one of the main differential diagnoses is adenofibroma in which the stromal component is, by definition, morphologically benign.
  • However, occasional adenofibromas recur or even metastasize.
  • As such, it has been suggested that all adenofibromas should be classified as adenosarcomas, albeit with low-malignant potential.
  • [MeSH-minor] Adenofibroma / pathology. Aged. Aged, 80 and over. Female. Humans. Ovarian Neoplasms / pathology. Postmenopause. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20179434.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down


35. Liu JL, Chu PY, Yeh KT, Huang RH: Borderline clear cell adenofibroma with extensive hemorrhagic necrosis. Hematol Oncol Stem Cell Ther; 2010;3(3):158-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borderline clear cell adenofibroma with extensive hemorrhagic necrosis.
  • Borderline clear cell adenofibroma of the ovary is rather rare since most of clear cell tumors are carcinomas.
  • We report a case of ovarian borderline clear cell adenofibroma in a 52-year-old postmenopausal woman.
  • The tumor had the characteristic histologic features of borderline clear cell adenofibroma except for central extensive hemorrhagic necrosis.
  • The prognosis of borderline clear cell adenofibroma is excellent.
  • [MeSH-major] Adenofibroma / pathology. Hemorrhage / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bleeding.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890073.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


36. Chiarelli S, Buriticá C, Litta P, Ciani S, Guarch R, Nogales FF: An immunohistochemical study of morules in endometrioid lesions of the female genital tract: CD10 is a characteristic marker of morular metaplasia. Clin Cancer Res; 2006 Jul 15;12(14 Pt 1):4251-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Immunohistochemical analysis of 53 instances of morular metaplasia comprising 1 cyclic endometrium and 52 endometrioid lesions associated with focal glandular complexity corresponding to 9 polyps, 4 atypical polypoid adenomyomas, 24 complex endometrial hyperplasias (18 with and 6 without atypia), 12 grade 1 endometrioid adenocarcinomas in early clinical stages of both uterus and ovary, and three ovarian adenofibromas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857799.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


37. Ikuta A, Tanaka Y, Mizokami T, Tsutsumi A, Sato M, Tanaka M, Kanzaki H: Benign endometrial adenofibroma and polyp in patients receiving tamoxifen: findings on transvaginal ultrasonography and magnetic resonance imaging. J Med Ultrason (2001); 2005 Jun;32(2):71-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign endometrial adenofibroma and polyp in patients receiving tamoxifen: findings on transvaginal ultrasonography and magnetic resonance imaging.
  • There have also recently been a few reports on the relation between tamoxifen and adenofibroma.
  • We present two case reports, one of a patient with a uterine adenofibroma and one of a patient with an endometrial polyp, both of whom received tamoxifen.
  • Postoperative microscopic examination confirmed the mass as an adenofibroma in case 1 and as an endometrial polyp in case 2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1999 Dec;35(14):1974-85 [10711240.001]
  • [Cites] Radiology. 2000 Jan;214(1):47-52 [10644100.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(4):363-71 [2246094.001]
  • [Cites] Abdom Imaging. 2002 Sep-Oct;27(5):592-4 [12173004.001]
  • [Cites] Int J Gynaecol Obstet. 1991 Oct;36(2):127-30 [1683314.001]
  • [Cites] Int J Gynecol Pathol. 2003 Apr;22(2):194-7 [12649677.001]
  • [Cites] Am J Obstet Gynecol. 1971 Aug 1;110(7):990-3 [5558981.001]
  • [Cites] J Comput Assist Tomogr. 1998 Mar-Apr;22(2):314-6 [9530402.001]
  • [Cites] Ultrasound Obstet Gynecol. 1996 May;7(5):363-6 [8774105.001]
  • [Cites] Ann N Y Acad Sci. 1959 Jan 9;75:568-85 [14428153.001]
  • [Cites] Obstet Gynecol. 1993 Aug;82(2):165-9 [8393156.001]
  • [Cites] Obstet Gynecol. 1993 May;81(5 ( Pt 1)):660-4 [8469450.001]
  • [Cites] J Clin Pathol. 1994 Sep;47(9):827-33 [7962652.001]
  • [Cites] Lancet. 1994 May 28;343 (8909):1318-21 [7910323.001]
  • [Cites] Radiology. 1996 Jul;200(1):105-10 [8657895.001]
  • [Cites] Ultrasound Obstet Gynecol. 1994 Jan 1;4(1):73-5 [12797230.001]
  • [Cites] Gynecol Oncol. 1984 Oct;19(2):216-21 [6489832.001]
  • (PMID = 27277125.001).
  • [ISSN] 1346-4523
  • [Journal-full-title] Journal of medical ultrasonics (2001)
  • [ISO-abbreviation] J Med Ultrason (2001)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; adenofibroma / magnetic resonance (MR) imaging / tamoxifen / transvaginal ultrasonography / uterus
  •  go-up   go-down


38. Bossuyt V, Medeiros F, Drapkin R, Folkins AK, Crum CP, Nucci MR: Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma. Int J Gynecol Pathol; 2008 Jul;27(3):390-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma.
  • Fallopian tube adenofibromas (FTAs) are considered rare, but their frequency has never been determined by systematic sampling of this organ.
  • To determine the morphological spectrum and prevalence of FTAs, we analyzed a consecutive series of fallopian tubes removed during surgery for a wide range of disorders.
  • Fallopian tube adenofibromas less than 3 mm were classified as incipient adenofibromas (iFTAs).
  • The association of FTAs with ovarian adenofibromas (OAs) was also evaluated.
  • Twenty-six of 28 (30% overall frequency) consecutively examined bilateral fallopian tube specimens contained adenofibromas (FTAs and iFTAs); all confined to the fimbria.
  • Whether the shared tumor phenotype in these 2 organs is coincidental or interdependent bears further investigation.
  • [MeSH-major] Adenofibroma / pathology. Fallopian Tube Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580316.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Eren F, Akpulat S, Gokaslan H: Primary leiomyoma of the ovary co-existing with serous cystadenofibroma. APMIS; 2005 Feb;113(2):145-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On cut section the tumor had a solid and a cystic component.
  • Sections taken from the solid component revealed a tumor composed of interlacing bundles of fusiform cells, resembling a leiomyoma.
  • Sections taken from the nodule in the cystic part revealed an adenofibroma.
  • As far as we know, this is the first case of a co-existing leiomyoma and serous cystadenofibroma in the ovary, and we think it will broaden the histological spectrum of primary ovarian leiomyomas.
  • [MeSH-major] Adenofibroma / pathology. Leiomyoma / pathology. Neoplasms, Multiple Primary / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15723690.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Actins
  •  go-up   go-down


40. Akbulut M, Zekioglu O, Terek MC, Ozdemir N: Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed tumor. Arch Gynecol Obstet; 2008 Sep;278(3):283-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed tumor.
  • OBJECTIVE: Adenofibroma is a form of mixed mesodermal tumor in which epithelial and stromal components are benign, and usually arises in the endometrium of postmenopausal women.
  • We report a case of lipoadenofibroma of the endometrium that appeared as an intracavitary mass, which is very unusual because endometrioid adenofibroma rarely contains mature adipose tissue, only the second such case described in detail.
  • CONCLUSION: We suggest that uterine adenofibromas with lipomatous areas belong to the family of mixed tumor of Mullerian origin.
  • [MeSH-major] Adenofibroma / pathology. Endometrial Neoplasms / pathology. Mixed Tumor, Mullerian / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236054.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


41. Soslow RA: Mixed Müllerian Tumors of the Female Genital Tract. Surg Pathol Clin; 2009 Dec;2(4):707-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed Müllerian Tumors of the Female Genital Tract.
  • Malignant mixed müllerian tumor (MMMT) and müllerian/mesodermal adenosarcoma are 2 of the most common mixed müllerian tumors of the female genital tract.
  • Adenosarcoma is also biphasic; it is composed of morphologically benign or low-grade appearing epithelial components and malignant stromal components.
  • The differential diagnosis of adenosarcoma includes MMMT, endometrial stromal tumor containing endometrioid glands, benign endometrial or endocervical polyp, adenofibroma, adenomyoma, including atypical polypoid adenomyoma, botryoid embryonal rhabdomyosarcoma (sarcoma botryoides), and endometriosis, including polypoid endometriosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier Inc. All rights reserved.
  • (PMID = 26838776.001).
  • [ISSN] 1875-9181
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Adenofibroma / Atypical polypoid adenomyoma / Carcinosarcoma / Female genital tract / Low-grade müllerian/mesodermal adenosarcoma / Malignant mixed mesodermal / Malignant mixed müllerian tumor / Polypoid endometriosis
  •  go-up   go-down


42. Chen XD, Shi HY, Zhang XF: [Clinicopathologic analysis of 102 cases of mixed epithelial and mesenchymal tumors of the uterus]. Zhonghua Fu Chan Ke Za Zhi; 2007 Apr;42(4):219-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of 102 cases of mixed epithelial and mesenchymal tumors of the uterus].
  • OBJECTIVE: To study the clinical and pathologic features, histological criteria and pathologic factors contributing to diagnosis of mixed epithelial and mesenchymal tumors (mixed müllerian tumors, MMT) of the uterus.
  • METHODS: A retrospective study of 102 cases of MMT of the uterus (74 adenofibromas including 9 recurrent cases, 3 atypical polypoid adenomyomas, 2 carcinofibromas, 10 adenosarcomas and 13 carcinosarcomas) was undertaken.
  • Benign MMT usually presented as exophytic polypoid masses extending into the uterine cavity or protruding through the external os, often broad-based, lobulated and papillary.
  • It was hard to distinguish low-grade malignant MMT from the benign ones by gross appearance.
  • MMT were classified according to whether these elements were benign or malignant.
  • Nine cases of adenofibroma without unique features for the diagnosis of adenosarcoma recurred at postoperative intervals of 3 to 96 months.
  • The recurrent adenofibromas may be a kind of borderline tumors with benign appearances and malignant behavior.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adenofibroma / pathology. Adenomyoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Epithelium / pathology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17631758.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


43. Hayasaka K, Morita K, Saitoh T, Tanaka Y: Uterine adenofibroma and endometrial stromal sarcoma associated with tamoxifen therapy: MR findings. Comput Med Imaging Graph; 2006 Jul;30(5):315-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine adenofibroma and endometrial stromal sarcoma associated with tamoxifen therapy: MR findings.
  • Tamoxifen therapy may result in a variety of endometrial proliferative lesions, including adenofibroma and endometrial stromal sarcoma (ESS).
  • This report describes the MR findings of adenofibroma and ESS associated with tamoxifen therapy.
  • When MRI demonstrates a uterine mass appearing as a heterogeneous mass in the endometrium or myometrium, adenofibroma and ECC must be considered as rare, but possible, diagnoses.
  • [MeSH-major] Adenofibroma / chemically induced. Magnetic Resonance Imaging. Sarcoma, Endometrial Stromal / chemically induced. Tamoxifen / contraindications. Uterine Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Endometrial Stromal Sarcoma.
  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890405.001).
  • [ISSN] 0895-6111
  • [Journal-full-title] Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society
  • [ISO-abbreviation] Comput Med Imaging Graph
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


44. Haberal A, Cil AP, Gunes M, Cavusoglu D: Papillary adenofibroma of the cervix: a case report. Ultrasound Obstet Gynecol; 2005 Aug;26(2):186-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenofibroma of the cervix: a case report.
  • Adenofibroma is an extremely rare benign biphasic neoplasm that is classified into the mixed epithelial and mesenchymal tumor group.
  • Preoperative diagnosis of this tumor is usually difficult.
  • We describe the case of a 55-year-old woman with papillary cervical adenofibroma, which appeared as a cervical mass containing multiple cystic components on transvaginal ultrasound.
  • This lesion appears to be clinically and histologically benign but must be differentiated from malignant lesions of the uterus, particularly from adenosarcoma, which can be suggestive of adenofibroma.
  • Accurate diagnosis of these benign tumors permits appropriate counseling of patients.
  • [MeSH-major] Adenofibroma / ultrasonography. Uterine Cervical Neoplasms / ultrasonography


45. Karlberg S, Lipsanen-Nyman M, Lassus H, Kallijärvi J, Lehesjoki AE, Butzow R: Gynecological tumors in Mulibrey nanism and role for RING finger protein TRIM37 in the pathogenesis of ovarian fibrothecomas. Mod Pathol; 2009 Apr;22(4):570-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mulibrey nanism is an autosomal recessive growth disorder caused by mutations in the TRIM37 gene encoding a protein of unknown function.
  • More than half of female patients with Mulibrey nanism develop benign mesenchymal tumors of ovarian sex cord-stromal origin.
  • In addition to tumors of the fibrothecoma group, 18% (4/22) of the patients were observed with epithelial neoplasias, including 2 ovarian adenofibromas, 1 ovarian poorly differentiated adenocarcinoma and 1 endometrial adenocarcinoma.

  • Genetic Alliance. consumer health - Mulibrey Nanism.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • SciCrunch. Clinical Genomic Database: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329943.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Protein Isoforms; 0 / TRIM37 protein, human
  •  go-up   go-down


46. Mondal SK: Adenofibroma and ectopic pregnancy of left fallopian tube: a rare coexistence. J Obstet Gynaecol Res; 2010 Jun;36(3):690-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenofibroma and ectopic pregnancy of left fallopian tube: a rare coexistence.
  • A rare coexistence of an adenofibroma and ectopic pregnancy in the left fallopian tube is reported.
  • Adenofibroma is a rare benign neoplasm of the fallopian tube, and the fallopian tube is the most common site of ectopic pregnancies.
  • However, coexistence of such rare tumor and ectopic pregnancy is extremely rare.
  • In the present case, the adenofibroma was found at the fimbrial end.
  • [MeSH-major] Adenofibroma / complications. Adenofibroma / pathology. Fallopian Tube Neoplasms / complications. Fallopian Tube Neoplasms / pathology. Pregnancy, Tubal / pathology

  • Genetic Alliance. consumer health - Ectopic Pregnancy.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20598059.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


47. Subhawong TK, Subhawong AP, Hamper UM: Serous adenofibroma of the testicle: case report and review of the literature. J Ultrasound Med; 2010 Jan;29(1):135-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous adenofibroma of the testicle: case report and review of the literature.
  • [MeSH-major] Adenofibroma / surgery. Adenofibroma / ultrasonography. Orchiectomy. Testicular Neoplasms / surgery. Testicular Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for adenofibroma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040787.001).
  • [ISSN] 1550-9613
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


48. Gurrera A, Alaggio R, Leone G, Aprile G, Magro G: Biliary adenofibroma of the liver: report of a case and review of the literature. Patholog Res Int; 2010;2010:504584
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biliary adenofibroma of the liver: report of a case and review of the literature.
  • We herein report the clinicopathologic features of a rare case of biliary adenofibroma (BAF) of the liver in a 79-year-old man.
  • Histological examination was typical of biliary adenofibroma, showing a proliferation of variable-sized tubulocystic structures embedded in a moderately cellular fibrous stroma.
  • Differential diagnosis with Von Meyenburg complex, biliary adenoma, biliary cistadenoma, congenital biliary cystsy, and hepatic benign cystic mesothelioma is provided.
  • The occasionally reported expression of p53 in biliary adenofibroma has suggested that this tumour could represent a premalignant lesion.
  • The absence of both cytological atypia and p53 immunoreactivity in our case confirms that BAF is a benign tumour with an indolent clinical behaviour.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151526.001).
  • [ISSN] 2042-003X
  • [Journal-full-title] Pathology research international
  • [ISO-abbreviation] Patholog Res Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2989712
  •  go-up   go-down


49. Konishi Y, Sato H, Fujimoto T, Tanaka H, Takahashi O, Tanaka T: Adenofibroma of the endometrium protruding into the vaginal cavity: findings on transvaginal ultrasonography, MRI and CT. J Obstet Gynaecol Res; 2006 Dec;32(6):623-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenofibroma of the endometrium protruding into the vaginal cavity: findings on transvaginal ultrasonography, MRI and CT.
  • Adenofibroma is a rare benign biphasic neoplasm that is classified into the mixed epithelial and mesenchymal tumor group.
  • We report the case of a 42-year-old woman with adenofibroma of the endometrium protruding into the vagina.
  • Transvaginal ultrasonography revealed the tumor as an intravaginal mass containing multiple cystic components.
  • Although preoperative diagnosis of this rare tumor is very difficult, the combination of MRI, CT, and ultrasonography offers a useful diagnostic tool.
  • [MeSH-major] Adenofibroma / ultrasonography. Endometrial Neoplasms / ultrasonography. Vagina / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17100829.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


50. Kohashi K, Oda Y, Nakamori M, Yamamoto H, Tamiya S, Toubo T, Kinoshita Y, Tajiri T, Taguchi T, Tsuneyoshi M: Multifocal metanephric adenoma in childhood. Pathol Int; 2009 Jan;59(1):49-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metanephric adenoma is the most commonly occurring member of the metanephric tumor family, which also includes metanephric adenofibroma and metanephric stromal tumor.
  • According to the World Health Organization classification, however, it is not commonly multifocal.
  • Reported herein is the case of a 9-year-old boy with multifocal metanephric adenoma.
  • On immunohistochemistry the tumor cells were positive for vimentin, cytokeratins (CAM5.2, AE1/AE3, and CK18), and WT1, but negative for cytokeratin 7 (CK7) and epithelial membrane antigen (EMA).

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19121092.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


51. Paşaoğlu O, Ciftçi E, Tel N, Ozalp S, Acikalin MF: Benign clear cell adenofibroma of the ovary. A case report with literature review. Gynecol Obstet Invest; 2007;64(1):36-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign clear cell adenofibroma of the ovary. A case report with literature review.
  • Most clear cell neoplasms of the ovaries are carcinomas; benign and borderline clear cell tumors are uncommon.
  • To date, only 12 cases of benign clear cell adenofibroma have been reported in the literature.
  • Here we report a case of benign clear cell adenofibroma of the left ovary in a 51-year-old postmenopausal woman.
  • In this article we discussed the criteria for the diagnosis of benign and borderline clear cell adenofibromas and reviewed the literature.
  • [MeSH-major] Adenofibroma / pathology. Adenofibroma / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery


52. Gatt N, Attard J, Degaetano J: Adenofibroma of the testis. J Clin Pathol; 2009 Jun;62(6):558-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenofibroma of the testis.
  • Adenofibromas of the testicular parenchyma are exceptional with only one case published in the literature.
  • Whereas adenofibromas of mullerian derivatives are well described, testicular tumours resembling surface ovarian epithelium are rare.
  • We describe a case of adenofibroma discovered incidentally while investigating for a hydrocoele in a 57-year-old patient.
  • Histological and immunohistochemical evaluation confirmed the lesion as being a serous adenofibroma with immunohistochemical properties analogous to its ovarian counterpart.
  • [MeSH-major] Adenofibroma / pathology. Testicular Hydrocele / pathology. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474357.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Keratin-7; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vimentin
  •  go-up   go-down


53. Katz L, Levy A, Wiznitzer A, Sheiner E: Pregnancy outcome of patients with dermoid and other benign ovarian cysts. Arch Gynecol Obstet; 2010 May;281(5):811-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy outcome of patients with dermoid and other benign ovarian cysts.
  • OBJECTIVE: To investigate pregnancy outcome of patients with dermoid and other benign ovarian cysts.
  • METHODS: A population-based study comparing all pregnancies of women with and without benign ovarian cysts was conducted.
  • A multivariate logistic regression model, with backward elimination, was constructed to find independent risk factors associated with benign ovarian cysts.
  • RESULTS: During the study period there were 212,114 deliveries, of which 93 occurred in patients with benign ovarian cysts.
  • Most of the lesions were benign cyatadenoma (41.9%), 36.7% were dermoid cyst, and 11.8% were adenofibroma, mostly diagnosed during cesarean delivery (76.3%).
  • The mean diameter at diagnosis was 9.05+/-7.6 cm for cystadenoma, 6.09+/-3.0 cm for dermoid cyst and 4.55+/-4.1 cm for adenofibroma.
  • The following conditions were significantly associated with benign ovarian cysts: hypertensive disorder [odds ratio (OR) 3.05; 95% confidence interval (CI) 1.87-4.97], and maternal age (OR 1.04; 95% CI 1.01-1.07).
  • CONCLUSION: The course of pregnancy of patients with dermoid and other benign ovarian cysts, including perinatal outcomes, is favorable.


54. Yemelyanova A, Mao TL, Nakayama N, Shih IeM, Kurman RJ: Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion. Am J Surg Pathol; 2008 Dec;32(12):1800-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In rare cases, the entire tumor is composed of macropapillae.
  • In these cases, the question of whether this is an invasive carcinoma or an unusual type of adenofibroma has been raised.
  • In addition to a detailed morphologic analysis, the mutational status of KRAS and BRAF in the macropapillary, noninvasive, and invasive MPSC components was analyzed by nucleotide sequencing.
  • There were 14 cases containing macropapillae (11 cases of LGSC, 2 cases of atypical proliferative serous tumor (APST) with microinvasion, and 1 case of APST with a focus of LGSC with macropapillae in perivaginal soft tissue).
  • Molecular analysis of the primary tumor components (macropapillary, noninvasive, and invasive MPSC and/or APST) was performed in 7 cases and of a lymph node metastasis with macropapillae in 1 case.
  • In one of these cases, macropapillae in the lymph node metastasis contained a KRAS mutation identical to the primary tumor.
  • The BRAF mutation identified in 1 case was identical in all components of the ovarian tumor.
  • The identical mutations in the macropapillae and the other tumor components in each case indicate that they are clonally related.
  • The finding of macropapillae within lymph nodes supports the interpretation that the macropapillary component is another manifestation of invasion in LGSC.
  • The recognition of this pattern is important, especially in cases when a tumor is composed entirely of macropapillae.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):1-7 [16462151.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7273-9 [16243797.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):883-7 [16806438.001]
  • [Cites] J Pathol. 2007 Jan;211(1):26-35 [17117391.001]
  • [Cites] Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9 [17218844.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):161-9 [17255760.001]
  • [Cites] Clin Med Res. 2007 Mar;5(1):35-44 [17456833.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jan;27(1):1-9 [18156967.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):419-32 [11257616.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):37-41 [12496696.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):484-6 [12644542.001]
  • [Cites] Am J Surg Pathol. 2003 Jun;27(6):725-36 [12766576.001]
  • [Cites] J Pathol. 2004 Mar;202(3):336-40 [14991899.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1511-8 [15111296.001]
  • [Cites] J Pathol. 2004 Jun;203(2):617-9 [15141374.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):934-48 [15297961.001]
  • [Cites] Cancer. 1994 Apr 1;73(7):1859-64 [8137211.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:208-18 [8747398.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1319-30 [8898836.001]
  • [Cites] Am J Surg Pathol. 1996 Nov;20(11):1331-45 [8898837.001]
  • [Cites] Am J Surg Pathol. 2005 Feb;29(2):218-24 [15644779.001]
  • [Cites] J Pathol. 2006 Dec;210(4):405-11 [17096315.001]
  • (PMID = 18779727.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA116184-01A2; United States / NCI NIH HHS / CA / R01 CA116184; United States / NCI NIH HHS / CA / R01 CA116184-01A2
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS77789; NLM/ PMC2706134
  •  go-up   go-down






Advertisement